Fidelity Investments’s Repros Therapeutics Inc. RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-1,171,544
| Closed | -$773K | – | 2806 |
|
|
2017
Q4 | $773K | Sell |
1,171,544
-314,600
| -21% | -$159K | ﹤0.01% | 2474 |
|
|
2017
Q3 | $476K | Sell |
1,486,144
-54,700
| -4% | -$19.2K | ﹤0.01% | 2488 |
|
|
2017
Q2 | $709K | Sell |
1,540,844
-47,200
| -3% | -$34.3K | ﹤0.01% | 2473 |
|
|
2017
Q1 | $1.91M | Sell |
1,588,044
-85,600
| -5% | -$107K | ﹤0.01% | 2364 |
|
|
2016
Q4 | $2.21M | Hold |
1,673,644
| – | – | ﹤0.01% | 2365 |
|
|
2016
Q3 | $3.5M | Hold |
1,673,644
| – | – | ﹤0.01% | 2262 |
|
|
2016
Q2 | $2.69M | Sell |
1,673,644
-612,958
| -27% | -$1.18M | ﹤0.01% | 2319 |
|
|
2016
Q1 | $2.22M | Sell |
2,286,602
-1,354,823
| -37% | -$1.32M | ﹤0.01% | 2363 |
|
|
2015
Q4 | $4.41M | Hold |
3,641,425
| – | – | ﹤0.01% | 2234 |
|
|
2015
Q3 | $27.1M | Hold |
3,641,425
| – | – | ﹤0.01% | 1526 |
|
|
2015
Q2 | $26M | Buy |
3,641,425
+496,279
| +16% | +$3.87M | ﹤0.01% | 1626 |
|
|
2015
Q1 | $27M | Buy |
3,145,146
+114,090
| +4% | +$1.02M | ﹤0.01% | 1615 |
|
|
2014
Q4 | $30.2M | Buy |
3,031,056
+569,973
| +23% | +$4.86M | ﹤0.01% | 1562 |
|
|
2014
Q3 | $24.4M | Buy |
2,461,083
+1,466,155
| +147% | +$21.7M | ﹤0.01% | 1654 |
|
|
2014
Q2 | $17.2M | Sell |
994,928
-33,200
| -3% | -$541K | ﹤0.01% | 1865 |
|
|
2014
Q1 | $18.2M | Buy |
1,028,128
+24,528
| +2% | +$475K | ﹤0.01% | 1797 |
|
|
2013
Q4 | $18.4M | Buy |
+1,003,600
| New | +$19M | ﹤0.01% | 1741 |
|
Fidelity Investments's RPRX Position: Q1 2018 in Review
Fidelity Investments sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 1,171,544 shares — an estimated $773K sold.
Fidelity Investments first reported a position in RPRX in Q4 2013 and held it in 17 quarters. The position peaked at $30.2M in Q4 2014. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.
- Fidelity Investments reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
- Fidelity Investments sold 1,171,544 Repros Therapeutics Inc. shares in Q1 2018, an estimated $773K.
- Fidelity Investments first reported a position in Repros Therapeutics Inc. in Q4 2013 and held it in 17 quarters.
- Fidelity Investments's Repros Therapeutics Inc. position peaked at $30.2M in Q4 2014.
- 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.
Based on Fidelity Investments's 13F filing for Q1 2018, filed 14 May 2018.